NovaDigm begins phase 2a trial of NDV-3A in Staphylococcus aureus
// www.pharmabiz.com
Американская компания NovaDigm начинает вторую фазу испытаний вакцины против Staphylococcus aureus (!). Вакцина NDV-3A. По заказу военных.
The study is being conducted with the Uniformed Services University of the Health Sciences (USU) and is enrolling US Army Infantry trainees at Fort Benning, GA.